Tumor growth, as a result of neovascularization, is further promoted via synergy between p53 mutation and upregulated vascular endothelial growth factor.
In addition, a study of 833 patients with primary breast carcinoma revealed a strong association between p53 mutations and increased vascular endothelial growth factor (VEGF) expression.
The possible association between congenital heart disorders and mutations in cardiac and vascular smooth muscle actin genes has been shown earlier in several reports [ 7, 8, 15].
For choroidal melanoma the relationship of known survival time with BRAF mutation, sex, cell type and vascular loops was tested one at a time by a Kaplan Meier analysis and the relationship of survival time with age and tumour diameter were tested using the 'Regression with Life Data' function of Minitab 13.1 (Minitab Inc., State College, PA, USA).
Adjusted analysis included age (continuous), sex, T stage (I-II, III, IV), N stage (0, 1, 2), M stage (0, 1), differentiation grade (high-intermediate vs. low and vascular invasion (+/−/unknown)), KRAS mutation status (wild-type, codon 12 mutation, codon 13 mutation) and BRAF mutation status (wild-type, mutated).
The present study demonstrated that the Bst mutation affecting Rpl24 alters cellular development and vascular patterning of the mouse retina.
The mutation in FLNB has displayed defects in skeletal and vascular development [26], but little is known about its function in colonocytes.
It should be noted that germline mutations in ATM severely impair glial cell functionality and vascular integrity, suggesting that Purkinje cell death and cerebellar degeneration in A-T may result from a dysfunctional neuro-astro-vascular unit.
A more recent gene-targeting experiment has shown that a null mutation of Prh also results in abnormalities of cardiac and vascular development [ 27].
Thus, zebrafish notch3 mutant phenotypes show aspects of CADASIL pathology, specifically compromised VSMC and vascular integrity despite the different nature of the mutations in notch3.
